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1. Introduction   
In principle, gene therapy is the introduction of a nucleic acid sequence(s) into target cells to 
prevent or cure a wide range of diseases. Such a therapeutic approach was initially directed
toward the correction of inherited disorders. For example, one strategy involves 
introduction of a corrected gene into cells followed by transplantation of the genetically 
modified cells into patients. But technological hurdles such inadequate transfer of genetic 
materials into cells, thus leading to low transgene integration, and safety concerns with gene
transfer methodologies have limited the use of gene therapy. However, significant 
improvements in gene delivery systems that are both efficient and safe have now directed
the growth of gene therapy, as evidenced by several hundred gene therapy-based clinical
trials being conducted worldwide. Advancements in all areas of gene therapy now allow for 
the development of genetically engineered immunocompetent cell-based therapies for 
cancer. 
The therapeutic role of immune cells to control malignancies has been well established. For 
example, immunocompetent hosts frequently reject transplanted tumors while tumors can 
easily be established in immunosuppressant hosts.  In vitro studies have demonstrated that 
immunocompetent cells exhibit powerful cytotoxicity toward a broad range of cancer cells
and tumorigenic animal models have shown that these cells can infiltrate tumors resulting
in tumor regression. Tumor infiltration by immunocompetent cells indicates favorable 
prognosis in various cancers, such as melanoma, colon, ovarian cancer, basal cell carcinoma,
and lung cancer (Haanen et al., 2006; Halliday et al., 1995; Inoue et al., 2000; Kerr et al., 1998;
Pages et al., 2005; Zhang et al., 2003). These observations have led to the development of cell 
based immunotherapy strategies to target cancer.  
However, intensive chemotherapy regimens, the frontline therapy to treat patients with 
advanced cancer, frequently lead to non-specific cellular toxicity to adoptively transferred 
immunocompetent cells and to hematopoietic stem cells. One strategy to combat drug-
induced toxicity is to genetically engineer immune cells to make them drug resistant.
Several genes, such as methylguanine methyltransferase (MGMT), dihydrofolate reductase
(DHFR), cytidine deaminase (CD), and multidrug resistant protein (MDR-1) have been 
identified that can confer drug resistance to anti-cancer immune cells, and advances in gene
therapy techniques have made it possible to test the feasibility of using the cDNAs encoding 
these sequences in drug resistant gene therapy studies. The ability to generate chemo­
resistant immune cells can be exploited to test novel anti-cancer therapies, such as “Drug 
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336 Gene Therapy - Developments and Future Perspectives 
Resistant Immunotherapy” (or DRI) whereby drug resistant immunocompetent cells can be 
administered in conjunction with chemotherapy.  Such a treatment modality can 
significantly enhance the generation of anti-tumor immunity that is quantitatively and
qualitatively superior to that achieved by either cellular immunotherapy or chemotherapy 
alone. DRI can also benefit from the ability to selectively expanding the modified cells in 
vivo by administering specific chemotherapeutic agents thereby mitigating the problem of
inefficient gene transfer to these cells. The anti-cancer effectiveness of DRI based therapy has
been successfully demonstrated using either drug resistant bone marrow or
immunocompetent cells with intrinsic cytotoxic capabilities. The therapeutic benefits 
afforded by a DRI based strategy can potentially be enhanced by the synergistic effects 
between chemotherapy and immunotherapy.  For example, chemotherapy mediated
lymphodepletion prior to adoptive transfer of drug resistant immunocompetent cells can 
mitigate immunosuppressive mechanisms that are advantageously exploited by progressive 
tumor cells to evade immune recognition. With the recent advances in ex vivo gene transfer 
technology, drug resistant variants of i) tumor specific lymphocytes, and their genetically
engineered counterparts such as those harboring transgenic αβ T cell receptor (TCR)/cancer 
antigen receptor (CAR) modifications, and ii) lymphocytes with non-specific cytotoxic 
potentials, can be bioengineered to treat various malignancies. 
However such a gene therapy based approach can be limited by inadequate transfer of
cDNA that encodes drug resistant genes. The ability to genetically engineer immune cells,
specifically hematopoietic cells, has greatly advanced in recent years. It is generally accepted 
that recombinant retroviral vectors, specifically those based on HIV-1) are the most efficient
gene transfer systems for the ex vivo modification of hematopoietic cells.  Retroviral systems 
have the advantage that i) recombinant viruses are now relatively easy to generate and 
characterize, ii) most components for retroviral transfer systems are commercially available,
iii) retroviral gene transfer results in stable integration of the transferred nucleic acid 
sequence into the genome of the target cell, and iv) depending on the target cells, the
efficiency of gene transfer can approach 100%.   
This chapter will discuss cancer immunotherapy with genetically engineered immune cells
and the feasibility of employing drug resistant variants of these cells during chemotherapy 
that can potentially augment such a cell therapy based approach. 
2. Combining drug resistant immune cell therapy with chemotherapy: A new
paradigm in cancer treatment 
Despite relentless efforts worldwide to improve upon conventional treatment modalities for 
cancer, chemotherapy remains a much needed frontline therapy.  Several cytotoxic agents, 
such as anti-metabolites, alkylating agents, anthracyclines, DNA methylasetransferase
inhibitors, platinum compounds and spindle poisons have been developed to kill cancer 
cells. However, they are not uniformly effective, and the introduction of these agents with 
novel state-of-the-art therapies, such as immunotherapies, is problematic. For example, 
these agents can be detrimental to the establishment of robust anti-tumor 
immunocompetent cells due to the non-specific cellular toxicity of many anti-cancer agents.
Intensive chemotherapy frequently administered to treat patients with advanced cancer can 
result in lymphopenia, which decrease the numbers and function of potential anti-cancer T 
cells in the blood thereby blunting the anti-tumor immune responses (Liseth et al., 2010). 
Tumor drug resistance can also develop, resulting in ineffective chemotherapy treatment 
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337Engineered Drug Resistant Cell-Mediated Immunotherapy 
(Michael & Doherty, 2005). In addition, induced secondary cancers and long-term 
survivorship issues limit the effectiveness of some cytotoxic chemotherapy agents (Perry et 
al., 1998). If the chemotherapy regimens that are transiently effective can be combined with 
immunocompetent cell therapies, then it is predicted that a significant improvement of anti-
neoplastic therapy can be achieved. However, because chemotherapy regimens are toxic to 
immunocompetent cells, the co-administration of these treatments reduces or eliminates the
effectiveness of the immunocompetent cells. 
One strategy to combat drug-induced toxicity is to genetically engineer immunocompetent
cells to make them drug resistant.  This strategy facilitated the development of a DRI-based 
anti-cancer technology that combines the therapeutic effectiveness afforded by drug 
resistant immunocompetent cells with conventional chemotherapy.  This strategy involves 
1) the use of lentivirus mediated applications to introduce cDNAs that encode for drug 
resistant genes into immunocompetent cells, and 2) administration of the genetically-
modified immunocompetent cells in conjunction with chemotherapy to enhance tumor cell 
clearance. The novel features of such a strategy are 1) it can be more potent in tumor 
elimination than the individual administration of chemotherapy or immunotherapy, 2) it
can easily be integrated with other conventional treatment modalities, such as surgery and
antibody/vaccine based immunotherapy, 3) it is applicable to patients with any disease
stages, and, 4) less aggressive chemotherapy can be applied during DRI therapy 
applications, thereby reducing the development of tumor drug resistance and induction of 
secondary cancers.  Several strategies have been identified that can  be used to confer drug
resistance to targeted cells, and advances in gene therapy techniques have made it possible 
to test the feasibility of using the cDNA encoding proteins that confer resistance in drug
resistance gene therapy studies. A number of proteins have been identified that confer drug 
resistance, but this chapter will focus on four that have already been used to confer 
resistance specifically to hematopoietic cells.
2.1 Drug resistant genes 
DHFR regulates folate homeostasis by controlling the synthesis of purines and pyrimidines.
Anti-folate drugs such methotrexate and trimetraxte, are inhibitors of DHFR. Gene therapy
strategies have exploited the use of DHFR mutants that can confer resistance to antifolates. 
For example, bioengineered hematopoietic stem cells (HSCs) harboring a mutated DHFR
transgene protects mice from an antifolate dose that is lethal to non-modified HSCs. (Allay 
et al., 1997, 1998a; Spencer et al., 1996,). However, HSCs bypass drug induced toxicity by 
increased nucleoside transport. To circumvent such effects, nucleoside transport inhibitors 
have been co-administered with antifolate drugs to significantly increase the population of 
cells modified with DHFR mutants, specifically L22Y (Allay et al., 1998b; Warlick et al., 
2002). 
The therapeutic efficiency of a single drug resistant based gene therapy can be significantly
enhanced by genetically engineering dual drug resistant anti-cancer cells. Such a strategy
can be particularly effective in treating tumors that respond to drug combinations that
exhibit synergistic (or additive) effects. The combination of methotrexate and a cytosine
nucleotide analog, cytosine arabinoside (Ara-C) has been successfully used in patients with 
Non-Hodgkins lymphoma (Fisher et al., 1993; Khouri et al., 1998). Ara-C is inactivated by
CD which is involved in the salvage of pyrimidine compounds and in pyrimidine 
metabolism.  The feasibility of bioengineering cells resistant to both an antifolate and Ara-C 
have led to the development of gene therapy strategies  based on the generation of dual
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338 Gene Therapy - Developments and Future Perspectives 
drug resistant cells (Sauerbrey et al., 1999). Transplantation of dual drug resistant bone 
marrow cells generated by the retroviral transfer of a fusion construct: mutDHFR-CD 
encoding for mutant DHFR and CD genes, into myoablated mice significantly reduced the
growth of established leukemia, while protecting hematopoietic cells (Budak-Alpdogan et 
al., 2004). 
During cancer progression, the tumor acquires resistance to multiple natural products by 
the expression of the MDR-1 gene. This gene encodes a membrane glycoprotein, known as
P-glycoprotein (P-GP) involved in the transport of metabolic byproducts across the cell 
membrane. The P-GP protein displays broad specificity towards several structurally
unrelated chemotherapy agents. Thus, pleitropic drug resistance can be conferred to cells by
the transfer of nucleic acid sequence that encodes for MDR-1.  MDR-1 gene was one of the 
first candidate genes to be exploited in the context of drug resistant gene therapy to confer 
protection to bone marrow cells. (Abonour et al., 2000; Bunting et al, 2000; Cowan et al, 1999; 
Moscow et al., 1999; Sellers et al., 2001; Sorrentino et al, 1992). These initial studies, and
others, led to the development of the field of drug resistance gene therapy for cancer. One 
strategy is to harvest HSCs from cancer patients and genetically modify them to express the
MDR-1 gene followed by transplantation into patients. During engraftment, chemotherapy
is administered to selectively enrich for modified cells in vivo, which leads to lower 
cytotoxicity upon repeated chemotherapy treatments. 
Among the drug resistant genes studied, MGMT is among the most promising. This gene
encodes for human alkyl guanine transferase (hAGT), a DNA repair protein that confers
resistance to the cytotoxic effects of alkylating agents, such as BCNU and temozolomide 
(Davis et al., 1997; Liu et al., 2002; Maze et al., 1996). Tumor cells have been shown to
express high levels of AGT, which can be an effective mechanism of tumor cell drug 
resistance.  To circumvent AGT-mediated resistance, alkylating agents have been 
administered in combination with inhibitors of AGT, namely 6-Benzyl Guanine (6-BG) 
(Dolan et al., 1989). Although 6-BG sensitizes tumor cells to alkylating agents, drug induced 
toxicities such as myelosuppression severely limit the use of these combined agents. To
overcome this limitation, several BG-resistant variants of AGT have been generated and 
used in gene transfer studies. Among them, the P140KMGMT variant has been well 
characterized with respect to drug resistant gene therapy. (Gerull et al., 2007; Larochelle et
al., 2009; Neff, et al., 2005; Pollok et al., 2003; Sawai et al., 2001; Zielske et al., 2003). 
2.2 Evaluation of drug resistant immunotherapy (DRI) 
The development of drug resistant genes along with the advancements in gene delivery 
systems has allowed for the chemoprotection of immunocompetent cells. Genetic 
engineering of drug resistant hematopoietic cells has been well documented (Allay et al, 
1998a, 1998b; Davis et al, 1997; Maze et al, 1996; Zhao et al, 2008). Transplantation of 
modified HSCs has been shown to protect the hematopoietic system from chemotherapy-
induced toxicity, and this strategy has been used to enrich the percentage of circulating 
gene-modified cells. The advantages to the establishment of such chemo-resistant bone 
marrow cells are two-fold.  First, chemotherapy can be administered, possibly at a higher 
frequency and at higher doses. For example, transplantation of the DHFR mutant L22Y­
modified HSCs allowed for the administration of the antifolate drug, trimetrexate (TMTX) at
concentrations that are lethal to animals not receiving the genetically altered bone marrow
cells (Allay et al., 1997, 1998; May et al., 1995; Spencer et al., 1996). Secondly, tumor targeting 
T lymphocytes can be expanded during chemotherapy challenges, leading to increased 
tumor infiltration and potentially increased tumor clearance 
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339Engineered Drug Resistant Cell-Mediated Immunotherapy 
The anti-cancer effectiveness of combining drug resistant HSCs, immune-modulating 
agents, and chemotherapy was evaluated by combining the administration of an antifolate 
based chemotherapy, trimetrexate (TMTX), along with anti-CD137-based immunotherapy in
mice transplanted with anti-folate resistant HSCs (McMillin et al., 2006). Mice were initially 
transplanted with L22Y-DHFR-modified bone marrow and were allowed to reconstitute
with drug resistant hematopoietic cells. The reconstituted mice were implanted with 
sarcoma cells, i.e. the AG104 sarcoma cell line. The tumor bearing animals were exposed to
treatments comprising of either anti-CD137, TMTX, or the combination of anti-CD137 and 
TMTX. Chemotherapy alone mediated tumor regressions only during the treatment phase. 
However, once this treatment ended all animals in this treatment group experienced rapid 
growth of their tumor.  Similarly, administration of immunotherapy alone regressed tumors
in the majority of animals, but only 40% of the animals achieve long-term tumor clearance. 
However, all animals treated with chemotherapy along with immunotherapy resulted in
complete tumor regressions. Such an observation confirmed the existence of possible 
synergism between immunotherapy and chemotherapy in the context of a drug resistant
immunotherapy strategy. Importantly, application of the DRI based strategy by combining
chemo-and immunotherapies can lead to the induction of immunological memory. Such an 
effect was demonstrated by infusing splenocytes isolated from mice in the combined
treatment group into untreated tumor bearing animals. The adoptive transfer of potential 
immunocompetent cell populations led to reductions in tumor burdens and extension of
survival of the recipient mice. These studies have important implications in designing 
treatment modalities to generate a robust antitumor response that may lead to eradicate 
residual tumor. Such a strategy will involve the co-administration of chemo-protected 
immunocompetent cells with chemotherapy that mediate a fast antitumor response to 
reduce tumor burden followed by the induction of immune memory cells that are sustained
over a long time to eliminate any persistent cancer cells.
Although initial studies focused on immunotherapy driven by HSCs, which is the source of 
all immune cells, other proof-of-concept studies were directed toward the evaluation of 
specific immunocompetent cells as mediators of DRI. For example, one study exploited the
use of genetically engineered drug resistant variants of the anti-cancer immune cells, NK92
and T-ALL104 cells, in combination with temozolomide (Dasgupta, et al., 2010).  These cells 
were selected based on their direct immunotherapeutic properties to mediate robust anti­
tumor properties without the requirement of MHC presentation (Gong et al., 1994; Tam et
al., 1999; Tonn et al., 2001). TALL-104 cells represent a leukemic T cell line that has surface 
markers typical of both cytotoxic T lymphocytes and natural killer cells and adoptive 
immunotherapy with TALL-104 cells has induced long-term complete or partial remissions 
in tumor bearing animals (Cesano et al., 1998; Geoerger et al., 2000). In this study, a SIV-
based lentiviral system was employed to deliver the drug resistant variant P140KMGMT 
into the immunocompetent cell lines NK-92 and TALL-104, and in the myelogenous 
leukemia cell line, K562, which is a target for both NK-92 and TALL-104 cells. Using in vitro
survival and cytotoxicity assays it was demonstrated that 1) the genetically-modified cells
developed significant resistance to the alkylating drug temozolomide when compared to the
untransfected wild type cells,  2) genetic modification of the immune effector cells did not
alter their ability to kill target cells, and 3) genetically altered cells were active in killing 
target cells after drug treatments, while the killing effectiveness of the unmodified effector 
cells is significantly diminished after a chemotherapy challenge. However, genetically 
modified drug resistant cells killed virtually all of un-modified K562 target cells in the
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340 Gene Therapy - Developments and Future Perspectives 
presence of drug, which was significantly higher compared to the killing effectiveness of the
non-modified effector cells.
These in vivo and in vitro proof-of-concept studies demonstrate that drug resistant 
immunocompetent effector cells are superior cytotoxic effectors during a chemotherapy 
challenge. This is a significant finding which can potentially be combined with current cell-
based and adoptive immunotherapies. Regression of large, vascularized tumors has been
shown in patients with refractory metastatic melanoma. However, for maximum
effectiveness a lympho-depleting regimen is necessary prior to autologous lymphocyte cell
transfer (Rosenberg & Dudley, 2004). Generation and expansion of drug-resistant 
lymphocytes ex vivo can allow, in this setting, for the administration of immunocompetent 
cell-based therapy concurrently with chemotherapy, potentially improving tumor clearance 
while anti-tumor immunity is established and maintained. In this scenario, non-transduced 
lymphocytes can continually be depleted using a selective chemotherapy treatment, which 
could be repeatedly applied during the administration of adoptive immunotherapy. The co­
administration of chemo- and immunotherapies could then lead to long-term tumor 
clearance. Thus, it is anticipated that the T lymphocytes with memory phenotypes are
suitable candidates to be incorporated into future DRI studies to target advanced cancer. 
3. Synergism between chemotherapy and immunotherapy can benefit drug 
resistant immunotherapy
Combining chemotherapy with immunotherapy is an attractive strategy to enhance the
effectiveness of both treatments, but initial combination strategies consisting of high-dose 
chemotherapy combined with interleukin-2 (IL-2) were no better than chemotherapy alone
(Pollera et al., 1994; Rinehart et al., 1992). However, studies in the last decade have 
demonstrated potential synergistic effects between chemotherapy and immunotherapy 
(Fridlender et al., 2010; Lake et al., 2005; Ramakrishnan et al., 2011). Conventional 
chemotherapy can augment immunotherapy in several ways: 1) induction of chemotherapy 
mediated-lymphodepletion leading to i) enhanced persistence of the tumor reactive T
lymphocytes, ii) increase in tumor trafficking by the tumor responsive T cells (Dudley et al, 
2002a, 2005), iii) modulation of immunosuppressive factors (Cui et al., 2009), and iv) 
promotion of differentiation of central memory effector cells (to augment vaccine based 
strategies) (Badovinac et al., 2005; Wrzesinski et al., 2007), and 2) chemotherapy induced 
sensitization of tumor to the immunocompetent cells by i) the induction of stress responsive 
molecules on tumor surface and ii)  increasing the availability of tumor antigens to “boost” 
the T cell response (Fridlender et al., 2010). Thus a DRI therapy approach that integrates 
both chemo- and drug resistant immune cell therapies can significantly benefit from such 
partnerships. 
3.1 Chemotherapy induced lymphopenia
Several clinical trials with melanoma patients support the concept that adoptive transfer of
genetically engineered T lymphocytes may not be sufficient to improve treatment outcomes
without lymphodepletion. For example, in the treatment of patients with advanced 
melanoma, anti-tumor response rate was observed only after adoptive transfer of T
lymphocytes (with or without engineered specificity towards melanoma antigens) with
lymphodepleting regimens (Dudley, et al., 2001, 2002b, 2005; Hughes et al, 2005). 
Lymphodepletion is thought to provide space in the lymphoid compartment thereby 
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341Engineered Drug Resistant Cell-Mediated Immunotherapy 
allowing robust establishment of the transferred lymphocytes (Klebanoff et al., 2005) which 
resulted in the induction of faster and more efficient immune response with enhanced anti­
tumor properties (Dudley et al., 2002; Rosenberg & Dudley, 2004; Wang et al., 2005a, 2005b).
Lymphopenia also induces the rescue of memory T cells as shown in the treatment of mice 
with established melanoma. For example, the anti-tumor efficacy of an immunotherapy 
comprising an oncolytic vaccinia virus expressing CD137 T-cell costimulatory molecule is 
significantly enhanced when animals were lymphodepleted prior to vaccination (Kim et al., 
2009). In addition, T regulatory cells (Tregs) have been implicated as having potent immune
suppressive functions, and clinical trials have indicated that depleting or inhibiting such
cells can increase anticancer efficacy (Phan et al., 2003). The number of Tregs can be reduced 
by chemotherapy and also by a combination of an adenoviral based immunogene therapy 
(Fridlender et al., 2010). 
3.2 Chemotherapy induced upregulation of stress antigens on tumor surface
Chemotherapy can sensitize tumors to augment immunotherapy by the up-regulation of 
tumor specific antigens that are recognized by the activating receptors expressed by NK and 
γδ T cells, thereby leading to an increase in tumor clearance (Nausch & Cerwenka, 2008). It
has been reported that various cancer cells exposed to drugs upregulate stress-associated
molecules MIC-A, MIC-B, and UL-16 binding proteins which are recognized by
immunocompetent NK and γδ T cells through their MHC-independent NKG2D/TCR 
pathways. Such innate HLA-independent interactions lead to the activation of anti-tumor 
properties of these cells, as has been demonstrated by γδ T cell mediated destruction of 
glioblastoma cells exposed to temozolomide, the frontline chemotherapy agent in the
treatment of patients afflicted with glioblastoma multiforme (GBM) (Lamb, 2009). This 
mode of immune cell-activation opens the possibility of testing a treatment modality that 
can combine immunotherapy based on drug resistant variants of NK or γδ T cells and
chemotherapy to target cancer types that express these activators during drug treatments. It 
was also demonstrated that in mouse models of colon and mammary cancer, applications of 
chemotherapeutic drugs upregulated the expression of a tumor cell surface receptor, 
mannose 6-phosphate receptor (Motyka et al, 2000). This receptor is implicated in the uptake
of granzyme B released by CTLs upon contact with tumor cells, thereby establishing a
synergy between chemotherapy and immunotherapy (Ramakrishnan et al, 2010). 
3.3 Enhancement of tumor antigen presentation
Chemotherapy induced tumor cell apoptosis can liberate massive amounts of tumor specific
antigens that are duly processed by antigen presenting cells and the processed antigens are 
presented, in association with MHC class I molecules, to CTLs leading to an increase in 
antigen presentation (Lake et al, 2005). Thus chemotherapy can augment immunotherapy 
by increasing antigen presentation, which can 1) lead to T lymphocyte expansion and 
increased lymphocyte infiltration of solid tumors and 2) mediate cancer vaccination effects. 
For example, it has been shown that chemotherapy can prime the host’s immunity and
enhance antitumor responses (Nowak et al., 2003a). Antitumor cytotoxic T lymphocytes 
(CTLs) showed increased proliferation because of increased tumor apoptosis when 
chemotherapy was administered, and incorporating immunotherapy with chemotherapy 
extended animal survival (Nowak et al., 2003b). Importantly, this study showed that the 
delivery of chemotherapy before immunotherapy is more effective than after 
immunotherapy (Nowak et al., 2003a). 
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342 Gene Therapy - Developments and Future Perspectives 
4. Potential immunocompetent cell sources for implementing DRI
Our knowledge about the host immune response to cancer has led to the development of 
immunocompetent cell-based therapeutics.  Two distinct classes of cells that are defined by 
their mechanism to invoke anti-tumor immunity have been exploited: i) the widely used 
tumor specific T lymphocytes, which must be primed prior to tumor cell killing, and ii) non­
specific MHC-unrestricted effector cells with intrinsic tumor killing properties.
4.1 Tumor-directed T lymphocytes
T cells mediate their potent anti-tumor effectiveness by their ability to recognize a wide
spectrum of antigens expressed on the tumor surface. These tumor associated antigens are
processed by the antigen presenting cells, such as dendritic cells into smaller peptides which
are presented to T cells in combination with MHC complexes.  T cell activation occurs after 
the recognition of the peptide-MHC complex via their antigen specific receptor, i.e. TCR­
CD3 complex. The T cell receptor is a heterodimer composed of either α and β or γ and δ
polypeptide chains. Each chain of the TCR is composed of a variable region (V) and a 
constant region (C). The V region determines the antigen binding specificity of the TCR. 
The vast majority of peripheral blood T lymphocytes and TCR+ thymocytes have αβ
TCR while epithelial T cells contain the γδ TCR. The TCR heterodimer is associated with the 
CD3 complex. The CD3 complex is necessary for i) the expression of TCR on the T cell
surface and ii) activation of T cells by signal transduction when the TCR binds to its specific
polypeptide primed MHC complex. Following the recognition of peptide-MHC, the CD3 
complex initiates signal transduction pathways to mediate cell proliferation, cytokine
secretion and activation of T cell anti-tumor properties (Chan et al.; 1992; Punt et al., 1994). 
Several tumor antigens such as melanoma/melanocyte differentiation antigens (MART-1
and gp100) and NY-ESO-1 cancer-testis antigen have been identified (Cormier et al., 1998;
Morgan, et al., 2003; Zhao et al., 2005). The tumor antigens can activate a large number of T
lymphocytes that can infiltrate the tumor (TIL). These immune cells have been widely 
employed during the administration of ACT to treat cancer.  ACT involves i) the isolation of 
tumor infiltrating lymphocytes, either from a surgically removed tumor or from the
peripheral blood, ii) ex vivo expansion of the selected cells in the presence of cytokines, and
iii) infusion of the expanded cells back into the patient, typically after ‘conditioning’ of the
patient with lymphodepleting regimens comprised of either chemotherapy or total body 
irradiation (TBI). It is now well established that ACT can establish or augment immunity
and eradicate malignant cells. 
Following the discovery of a large number of tumor antigens, TILs directed against such
antigens have been successfully generated, mainly from melanoma but also from renal cell 
carcinoma and glioma (Dillman et al., 1991; Figlin et al., 1997; Kradin et al., 1989; 
Quattrocchi et al, 1999). TILs mediated tumor regression when transferred into tumor-
bearing mice. ACT with TILs directed against melanoma antigens have proven successful
since patients with melanoma are immunized against antigens expressed by their own 
tumors and melanoma tumors generate relatively higher quantities of  melanoma antigen
specific T lymphocytes. However, the use of TILs in the treatment of patients with cancer 
other than melanoma has met with limited success, possibly due to the presence of low 
number of cytotoxic T lymphocytes within TILs (Finke et al., 1994; Hom et al., 1993; 
Schwartzentruber et al., 1992). Therefore, improvements in the usefulness of TILs are
needed, and DRI studies are in progress to determine if such modifications can improve the 
therapeutic potential of these cells.
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343Engineered Drug Resistant Cell-Mediated Immunotherapy 
4.1.1 Chimeric αβ TCR modified T cells
In general, αβ T lymphocytes display low affinity TCRs. Therefore, success with ACT with 
tumor directing αβ T lymphocytes is limited by the difficulty in isolating high affinity αβ T 
lymphocytes that exist in low numbers in vivo and in ex vivo expansion of these cells to
generate adequate quantities for in vivo anti-tumor efficacy. Furthermore, tumor derived 
immunosuppression mechanisms reduce the number of tumor specific αβ T cells in
circulation. As a means of enhancing the anti-cancer efficacy of αβ T lymphocytes, these
cells can be genetically modified to express transgenic α and β TCR chains, which can be
derived from T cell clones specific for tumor-associated antigens. These genetically
engineered CTLs harboring a transgenic αβ TCR, in addition to their native αβ TCR, acquire
the same antigen specificity as the high affinity T cells from which the TCR was cloned. 
Several CTLs harboring transgenic TCRs have now been developed that are directed
specifically to tumor antigens, such as MART-1, gp100, NY-ESO-1 and CEA,  resulting in
tumor elimination in animal models (Abad, et al., 2008; Morgan, et al., 2003; 2006; Kessels et
al., 2001; Stanislawski et al., 2001; Wargo et al., 2009; Xue et al., 2005). Bicistronic viral 
vectors encoding cDNA sequences for both α and β chains have been successfully
incorporated into retroviral based strategies to  transfer αβ transgenic TCR into T 
lymphocytes (Yang et al., 2008). The functional efficacies of the engineered CTLs have also 
been improved by codon optimizing α and β sequences that result in increased surface
expression of the transgenic TCRs (Jorritsma et al., 2007; Scholten et al., 2006). The chimeric
αβ T cells can be rapidly expanded ex vivo to produce sufficient quantities of tumor reactive
cells and after adoptive transfer to patients display potent MHC-restricted cytotoxic activity
against tumor cells expressing the specific epitope. ACT with tumor directed chimeric αβ T 
lymphocytes have been widely used to treat various malignancies, particularly melanoma,
because of the ease of isolating and expanding melanoma reactive CTLs ex vivo. 
However, the genetic engineering of CTLs that express the transgenic αβ TCR along with 
their endogenous TCR has inherent disadvantages. The endogenous TCR can compete with
the transgenic αβ TCR to bind to the initiator CD3 molecule. Consequently, the chimeric αβ
TCR-modified CTLs may suffer from reduced activation leading to a decrease in affinity of 
the transgenic αβ TCR towards specific tumor antigens. Furthermore rearrangements
between the chimeric and the naïve TCR chains can induce new and unwanted reactivities. 
To combat such undesired consequences TCR negative lymphocytes have been modified to 
harbor αβ transgenic TCR while the sequences of such chimeric αβ TCRs have been  
redesigned to reduce cross competition within T lymphocytes harboring naïve TCR (Kuball
et al., 2007; Robbins et al., 2008). 
4.1.2 Cancer Antigen Receptor (CAR)-modified T cells
Adoptive immunotherapy for cancer utilizes additional bioengineering strategies adaptable 
to drug resistant immunotherapy whereby T lymphocytes are genetically modified to 
express chimeric antigen receptors. In contrast to chimeric αβ TCR, CAR combines antigen 
specificity derived from a tumor antigen specific monoclonal antibody fragment and T cell 
proliferation signal moieties. Upon infusion into patients, immunocompetent T cells 
genetically engineered to express CAR can specifically recognize and respond to soluble, 
immobilized and/or tumor antigens and, to date, a range of CARs targeting a variety of
surface molecules expressed by many solid tumors and hematological malignancies, such as 
B cell malignancies and melanoma, have been developed (Kohn et al., 2011). 
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344 Gene Therapy - Developments and Future Perspectives 
The potency of CAR modified CTLs have evolved through several generations of design 
changes (Cartellieri et al., 2010). First generation CARs are constructed by the fusion of the
single-chain Fv (scFv) moiety, derived from the light and variable chains of a monoclonal
antibody, directed against tumor associated antigens with the transmembrane and 
cytoplasmic signaling domains derived from the CD3 ζ chain. The CD3 domain provides 
activation signal to the CAR for the induction of cytotoxicity towards the tumor expressing 
the protein that is recognized by the scFV. Thus CAR integrates the antigen specificity of an 
antibody and anti-tumor properties of CTLs. However, bioengineered CTLs were poorly 
activated by the first generation CARs, possibly due to in sufficient co- stimulatory signaling 
as evident by low response rates in clinical trials in subjects with various malignancies, such 
as lymphoma, and ovarian cancer (Kershaw et al., 2006; Lamers et al., 2006). To circumvent
this issue, various signaling domains from costimulatory molecules such as CD28, OX40, 
and CD137 (4-1BB) were fused to the cytoplasmic tail of the CAR which improved the anti­
tumor efficacies of the CTLs modified with the second generation CAR in preclinical models 
(Kowolik et al, 2006). To further enhance the potency of the engineered CTLs, recent third
generation CARs are designed to incorporate tripartite signaling domains, such as CD3ζ­
CD28-41BB or CD3ζ-CD28-OX40.  Several vector systems have been designed to introduce 
the chimeric receptors into T cells. Such systems include γ-retroviral vectors, lentiviral 
vectors and transposon based (sleeping beauty) constructs (Hackett et al., 2010; Westwood
& Kershaw, 2010). 
CAR based anti-neoplastic cellular therapy can be applicable to patients with any HLA type
since CARs use antibodies as the component that recognize the target antigen and thereby 
the CAR-modified cells act in “HLA non-restricted” fashion to destroy their target. Thus
CAR mediated cellular immunotherapy is refractory to the immune evasion strategies by
tumors, such as downregulation of HLA class I molecules or failure to process or present 
proteins. However, CAR can be targeted only against extracellular (surface) antigens, which 
represent only a subset of potential tumor-associated antigens. To circumvent limitation, 
CARs have also been designed to recognize carbohydrates and glycolipids (Dotti et al, 2005;
Sadelain et al., 2009).  It should also be noted that currently, murine derived antibodies are
employed to design the antibody components of most CARs, which raises the possibility of 
evoking immune responses against the CAR-engineered cells after infusion. 
4.2 MHC-unrestricted immune cells
Conventional cell based immunotherapeutic strategies that are based on the activation of
HLA-restricted lymphocytes have limited anti-tumor response. This is due to i) frequent 
down regulation of HLA on the tumor cell surface thereby mitigating the activity of
adaptive immune responsive cells, ii) secretion of immunosuppressive factors by the tumors 
and iii) limited expression of tumor antigens in small subset of the tumor cells. Thus novel
strategies that harness the anti-cancer responsive-innate immune cells, such as NK92 cells
and a minor subclass in the T lymphocyte repertoire, γδ T cells present a promising 
alternative to conventional adaptive cell based therapy approaches to treat cancer. 
4.2.1 Natural killer (NK) cells 
NK cells comprise a unique subset of lymphocytes, distinct from T and B cells, and are 
members of the innate immune response cells with potent immunosurveillance properties.
These cells do not require any prior immune sensitization by the host to lyze tumor cells
www.intechopen.com
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
345Engineered Drug Resistant Cell-Mediated Immunotherapy 
(Herberman et al., 1975; Kiessling et al., 1975; Klingemann, 2005). Early pioneering work 
demonstrated the therapeutic benefits of adopting innate immune responsive killer cell 
based strategies, specifically with LAK cells along with IL2, to target advanced metastatic 
renal cell carcinoma and melanoma (Rosenberg, et al., 1985). However, later studies found
similar benefits with administrations of IL2 alone (Law et al., 1995).  It was initially thought
that NK cells exhibit potent cytotoxicity towards transformed cells that express altered MHC
molecules (missing self recognition) while sparing normal cells that express unaltered MHC 
molecules (self recognition) via the activation of the inhibitory receptors. However, NK cells 
are able to efficiently attack some target cells that express normal levels of class I MHC 
molecules, while some other cells are not sensitive to NK cell-lysis despite low or absent 
class I MHC expression. It is now established that NK cells express NKG2D (natural killer 
group D) receptors that are activated by the recognition of ligands that are strongly 
upregulated in stressed tumor cells (Bauer et al., 1999; Cosman et al., 2001). Surprisingly, 
normal non-stressed cells of bone marrow activated peripheral blood T lymphocytes and 
even normal non-hematopoetitic cells express NKG2D ligands. The specific roles of NK cells
towards each of these cell types are under investigation (Eagle et al, 2009). The use of 
autologous NK cells has met with limited success (Burns et al, 2003; Law et al, 1995; 
Rosenberg et al, 1985). Consequently, focus has shifted to the use of allogeneic NK cells to
treat cancer (Miller, et al., 2005; Ljunggren & Malmberg, 2007). 
Several NK cell lines have been developed that share functional and phenotypic
characteristics of activated NK cells. Among these, the most promising is the NK92 cell line,
an allogeneic cell line derived from a patient with non-Hodgkin’s lymphoma (Gong et al.,
1994; Tam et al., 1999; Tonn et al., 2001). There are several advantages to employing NK92 
cells, or similar cell lines, in adoptive immunotherapy: i) they represent a well characterized 
immunophenotype with powerful anti-tumor properties that are independent of MHC 
restrictions, ii) these cells express activating receptors and lack most of the inhibitory killer 
immunoglobulin-like receptors, KIRs (Middleton et al., 2002), thus retaining their 
cytotoxicity against cancer cells that up-regulate MHC class I molecules and iii) the ease of 
culturing these cells to generate adequate quantities for clinical use.  Currently, there are
several clinical trials are underway to evaluate the efficacy of NK cell mediated cancer 
immunotherapy.
4.2.2 γδ T cells 
γδ T cells are defined by their expression of T cell receptors (TCR) encoded by γ and δ loci.
γδ T cells combine features of both innate and adaptive immune systems. These cells exhibit 
direct anti-tumor properties via MHC-independent NKG2D and TCR pathways. γδ T cell 
based immunotherapy strategies have been extensively tested to target GBM (Bryant et al., 
2011; Lamb, 2009). Thus, γδ T cells that require no priming and mediate their cytotoxicity by 
direct recognition of chemotherapy induced antigens on the surface of GBM cells represent 
an attractive cellular immunotherapeutic candidate for GBM therapy. In this context, genetic 
engineering of γδ T cells that are resistant to temozolomide, the frontline chemotherapy 
agent to treat GBM, presents an attractive scenario whereby drug resistant γδ T cell based 
immunotherapy can be administered in combination with a traditional chemotherapeutic 
agent. 
Freshly isolated and expanded γδ T cells from the peripheral blood of healthy donors can  
destroy neuroblastoma cells while adoptive transfer of γδ T cells, expanded under clinical 
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grade conditions, in combination with immunocytokines are effective against disseminated 
neuroblastoma established in mice (Otto et al., 2005; Schilbach et al., 2000). Recently, a
clinical study of 25 patients with advanced stages of various solid tumors demonstrated that
γδ T cell based immunotherapy is beneficial and importantly, such a therapy did not induce
any serious treatment related side effects (Noguchi et al., 2011). However, these cells
comprise a minor fraction (1-5 %) of the peripheral blood lymphocytes and consequently γδ
T cell based immunotherapy requires prior expansion ex vivo. Protocols to expand γδ T cells
using therapeutic grade materials have been developed to facilitate the initiation of clinical 
trials to treat patients with cancer (Noguchi et al., 2011). 
5. Conclusion 
Although the combination of surgery and chemotherapy is effective for some types of 
cancer, there are obvious limitations to our current state-of-the-art treatment of cancer. 
Among the various potential therapeutic modalities being used to treat cancer,
immunocompetent cell-based therapy is becoming an effective alternative, which is possible 
because of the advancements in technologies used to genetically engineer these cells. As 
described in this chapter, various engineering strategies have potentiated the acquired or
intrinsic anti-tumor response of immunocompetent cells. It is now anticipated that 
bioengineered cell-based therapies, when partnered with conventional chemotherapies, can
invoke an anti-tumor response that is superior to results achieved by the individual
therapies. Both the chemotherapy and cellular therapy fields are focused on determining 
optimal strategies for combining these therapies, and many types of combination 
approaches are being evaluated.  Several successes using combination strategies have 
already been reported. For example, administration of chemotherapy following vaccine
based immunotherapy have shown therapeutic efficacies in patients with several types of 
cancer, such as small-cell lung cancer, prostate cancer and advanced stages of  ovarian, 
breast, colorectal, renal and prostrate cancers (Antonia et al., 2006; Arlen et al, 2006; Gribben 
et al. 2005). Strikingly, when chemotherapy was added to tumor bearing mice previously 
administered with immunotherapy, both the percentage and potency of tumor specific 
immunocompetent cells were increased (Fridlender, et al., 2010), indicating that
immunotherapy and chemotherapy can be combined, but combining the two treatment
modalities is not straightforward. Although potential synergism exists between 
chemotherapy and immunotherapy, drug mediated myelosuppressive effects limits the 
employment of immune-effector cells during chemotherapy applications. DRI can allow for 
the administration of a dual therapy regimen, which combines genetically engineered drug
resistant cell-based therapy with chemotherapy.  Proof-of-concept studies evaluating DRI
have yielded promising results, which show robust anti-tumor responses can be maintained
during chemotherapy challenges. However, challenges remain as to i) the manipulation of 
the immune effector cells, ii) the timing of infusion of the bioengineered cells with
chemotherapy, and iii) the long term safety profiles of such treatments. But the potential 
benefits afforded that can be accomplished by employing engineered immune cells, and
specifically modified cells that have been engineered as drug resistant cells,  warrants the 
continued development of such therapeutic approaches. The use of cDNA sequences that
confer drug resistance to immunocompetent cells can eventually be directed toward a broad
range of human malignant diseases that continue to have unmet medical needs.
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